<DOC>
	<DOCNO>NCT00418587</DOCNO>
	<brief_summary>The purpose study test safety effectiveness different dos vitamin D patient Systemic Lupus Erythematosus ( SLE ) . A long term goal determine vitamin D could use treatment and/or preventative SLE .</brief_summary>
	<brief_title>Vitamin D Therapy Patients With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>SLE ACR criterion ( revised 1997 ) African American , participate SLE Gullah Health ( SLEIGH ) Study Outpatient Stable disease BILAG A B system past 4 week Stable prednisone ( equivalent corticosteroid ) dose ≤ 20 mg/day ≥ 4 week prior study entry Baseline 25 ( OH ) D concentration &lt; 30 ng/ml Willingness discontinue vitamin D supplement and/or multivitamin contain vitamin D participate study Age 18 85 year Ability complete questionnaire English Ability give inform consent Presence hypercalcemia ( &gt; 10.4 mg/dL ) , hypercalcuria ( urinary calcium/creatinine ratio ≥ 0.8 mmol/mmol ) know primary hyperparathyroidism Liver disease ( serum ALT , AST &gt; 2x normal ) total serum bilirubin &gt; 1.5x normal History renal stone Current treatment dose cyclophosphamide Dialysis creatinine &gt; 2.5 mg/dL Pregnancy Current drug alcohol abuse Anticipated poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Lupus</keyword>
</DOC>